Pierre-Emmanuel Brachet
A5113852754- PARP inhibition in cancer therapy
- Glioma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Radiation Therapy and Dosimetry
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- European Political History Analysis
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Cell death mechanisms and regulation
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Renal and related cancers
- Historical Studies and Socio-cultural Analysis
- Radiopharmaceutical Chemistry and Applications
- Frailty in Older Adults
- Lung Cancer Research Studies
- Nutrition and Health in Aging
- Lymphoma Diagnosis and Treatment
- Historical Art and Culture Studies
Centre François Baclesse
2016-2025
Université de Caen Normandie
2015-2024
Centre François Baclesse
2014-2024
Medical University of Graz
2023
Arcagy Gineco
2022
Onco Lille
2022
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers
2018
Inserm
2015-2017
Cancers et Préventions
2017
Normandie Université
2017
Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development new radiosensitizer crucial to improve patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be promising class radiosensitizer. aim this study evaluate Olaparib, PARPi,...
Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have detrimental effect on outcomes for these patients.To compare the feasibility, efficacy, and safety single-agent every 3 weeks, weekly carboplatin-paclitaxel, or every-3-weeks cancer.This international, open-label, 3-arm randomized clinical trial screened 447 women 70 years newly diagnosed stage III/IV cancer by...
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), placebo-controlled double-blinded randomized phase III trial, enrolled patients recurrent epithelial OC, one to two previous chemotherapy lines, PFI Eligible were randomly...
<p>B. Progression-free (left) and overall (right) survival according to MGMT status among the patients enrolled in two sequential olaparib dose-escalations of trial.</p>
Abstract Background Perioperative chemotherapy and surgery are a standard of care for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, the prognosis remains poor this population. The FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) regimen is considered as new perioperative strategy, despite associated 5-year overall survival rate (OS) amounting 45% following radical surgery. Immunotherapy antibodies that inhibit PD-1/ PD-L1 interaction has...
Abstract Background: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve outcomes. We implemented a phase 1-2a trial to assess safety and efficacy combined with standard radio-chemotherapy as in unresected patients. herein present results 1. Methods: Based on Stupp regimen, two sequential dose escalations were performed distinguish radiotherapy period maintenance for...
<p>A. Progression-free (left) and overall (right) survival among the 30 patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>C. Progression-free (left) and overall (right) survival for first second olaparib dose-escalation cohorts of the trial. was defined as time elapsed from treatment start to RANO progression or death any cause (whichever occurs first); Overall cause.</p>
<p>Magnetic Resonance Imaging (gadolinium, FLAIR and perfusion sequences from left to right) at baseline (top) 60 months (bottom) after start of treatment in first line a partially resected glioblastoma patient.</p>
<div>AbstractPurpose:<p>Radiochemotherapy remains the mainstay of glioblastoma (GBM) first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve GBM outcomes. We implemented a phase I to IIa trial assess safety and efficacy combined with standard radiochemotherapy as in patients unresected GBM. herein present results I.</p>Patients Methods:<p>Based on Stupp regimen, two sequential dose escalations were performed...
Abstract Background: Virus-associated tumors, characterized by immune evasion and angiogenic signaling, remain a therapeutic challenge. Human papillomavirus (HPV)-associated cancers such as cervical, anal, oropharyngeal represent significant subset of virus-associated tumors are mediated viral oncoproteins E6 E7. Toll-like receptor 7/8 (TLR7/8) agonists EIK1001 have been shown to activate innate pathways, enhancing antigen presentation inducing robust adaptive response. This is particularly...
Abstract Background Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy first line standard of care for fit patients advanced UC. However, despite response rate (RR) approximately half receiving chemotherapy, durable responses are rare (median progression-free progression (PFS) around 8 months). Recently, immune checkpoint inhibitors (ICI) have emerged as new therapeutic options. Among them, Avelumab,...
Introduction: DNA damage repair genes are altered in 20–35% of metastatic castration-resistant prostate cancer (mCRPC). Poly-ADP (Adénosine Diphosphate)-ribose polymerase inhibitors (PARPi) showed significant activity for these selected tumors, especially with homologous recombination (HRR) deficiency. These alterations could also predict platinum sensitivity. Although carboplatin was inconclusive unselected mCRPC, the literature suggests an anti-tumoral mCRPC HHR gene alterations. We aimed...
Abstract Background Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients’ perspectives on the burden of prolonged maintenance therapy have not been reported prospective trials or routine practice. Methods In real-life multicenter NiQoLe study, patients with PSROC received ISD niraparib. The primary objective was to describe physician-reported adverse events (AEs) leading treatment modification...
Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect the increase haemoglobin level (HbL) during with a suspected correlation better outcome. Our objective was to examine whether HbL three months axitinib associated prognosis. Retrospective multicentre analysis including patients mRCC treated at least from 2012 2014. Progression-free survival (PFS) analysed by Cox model according gender, International Metastatic Renal Cell...
Brain metastases often occur in cancer evolution. They are not only responsible for death but also disorders affecting the quality of life and cognitive functions. Management brain usually consists multi-modality treatments, including neurosurgery, whole radiotherapy (WBRT), more recently radiosurgery (SRS) or fractionated stereotactic (FSRT), systemic treatment (chemotherapy targeted therapy), combined with corticosteroids. Almost 20% can present recent (within 15 days) bleeding signs on...
Introduction We sought to develop a novel method for fully automated, robust quantification of protein biomarker expression within the epithelial component high-grade serous ovarian tumors (HGSOC). Rather than defining thresholds given biomarker, objective this study in small cohort patients was applicable many clinical situations which immunomarkers need be quantified. aimed quantify by correlating it with heterogeneity staining, using non-subjective choice scoring based on classical...